Vertex Pharmaceuticals VRTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 344.7%-0.9pp | 345.5%-5.4pp | 351%-1.0pp | 352%0.0pp | |
| EBITDA margin | 106.5%+64.5pp | 42.1%-129pp | 171.4%-17.0pp | 188.4%+26.6pp | |
| Free cash flow margin | 29.7%+56.2pp | -26.5%-187pp | 160.4%— | —— | |
| Returns | |||||
| Return on invested capital | 71.8%+44.5pp | 27.3%-91.2pp | 118.5%-23.9pp | 142.4%+12.6pp | |
| Efficiency | |||||
| Asset turnover | 2×0.0× | 2×-0.1× | 2.1×-0.3× | 2.4×0.0× | |
| Inventory turnover | 5.1×-2.0× | 7.1×-2.1× | 9.2×-2.3× | 11.4×-0.5× | |
| Liquidity | |||||
| Current ratio | 10.4×-0.8× | 11.2×-5.3× | 16.5×-2.3× | 18.8×+0.7× | |
| Quick ratio | 8.9×-1.2× | 10.1×-5.6× | 15.7×-2.4× | 18.2×+0.7× | |
| Cash ratio | 4.9×-1.4× | 6.3×-0.1× | 6.4×+1.1× | 5.3×-0.2× | |
| Leverage | |||||
| Debt-to-equity | 0.4×+0.1× | 0.3×+0.1× | 0.2×-0.1× | 0.3×-0.1× | |
| Debt-to-assets | 0.3×+0.1× | 0.2×+0.1× | 0.2×-0.1× | 0.2×-0.1× | |
| Interest coverage | 845×+767× | 78×-254× | 332.1×— | —— | |
| Per Share | |||||
| Book value per share | $269.49+7.0% | $251.79+2.5% | $245.71+27.8% | $192.33+32.6% | |
| Valuation | |||||
| Market capitalization | $455.56B+0.6% | $452.7B+23.5% | $366.56B+27.8% | $286.89B+38.0% | |
| Enterprise value | $442.91B+2.0% | $434.3B+25.0% | $347.55B+25.5% | $277.03B+38.0% | |
| Price / sales | 39.5×-3.5× | 43×+4.7× | 38.3×+4.5× | 33.8×+3.8× | |
| Price / book | 26.2×-1.8× | 28×+5.1× | 22.9×-0.3× | 23.2×+1.1× | |
| EV / sales | 38.4×-2.8× | 41.2×+4.9× | 36.3×+3.7× | 32.7×+3.7× | |
| Free cash flow yield | 3.8%+6.4pp | -2.6%-19.5pp | 16.9%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
